| Literature DB >> 24904839 |
Tao Lin1, Erin B Troy2, Linden T Hu2, Lihui Gao1, Steven J Norris1.
Abstract
Transposon insertion provides a method for near-random mutation of bacterial genomes, and has been utilized extensively for the study of bacterial pathogenesis and biology. This approach is particularly useful for organisms that are relatively refractory to genetic manipulation, including Lyme disease Borrelia. In this review, progress to date in the application of transposon mutagenesis to the study of Borrelia burgdorferi is reported. An effective Himar1-based transposon vector has been developed and used to acquire a sequence-defined library of nearly 4500 mutants in the infectious, moderately transformable B. burgdorferi B31 derivative 5A18NP1. Analysis of these transposon mutants using signature-tagged mutagenesis (STM) and Tn-seq approaches has begun to yield valuable information regarding the genes important in the pathogenesis and biology of this organism.Entities:
Keywords: Borrelia burgdorferi; Lyme disease; bacterial physiology; microbial pathogenesis; mouse models; transposon mutagenesis
Mesh:
Substances:
Year: 2014 PMID: 24904839 PMCID: PMC4033020 DOI: 10.3389/fcimb.2014.00063
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Challenges to genetic manipulation of .
| Fragility of organisms | Specialized methods for preparation of |
| Slow growth rate; inefficient isolation of mutants | Utilization of either plating or limiting dilution approaches |
| Plasmid loss during | Minimization of |
| Careful monitoring of plasmid content | |
| Use of shuttle vectors to replace virulence-associated plasmid-encoded genes (e.g., | |
| Restriction-modification (R-M) systems | Disruption of R-M genes |
| Use of strains lacking plasmids (lp25, lp56) that encode R-M systems | |
| DNA methylation prior to transformation |
Figure 1Diagram of the transposon vector pGKT-STM1, modified from the . Features of pGKT include the use of B. burgdorferi flgB and flaA promoters to increase the efficiency of expression of the Himar1 c9 transposase and the gentamicin and kanamycin antibiotic resistance markers. The transposable element is flanked by the inverted tandem repeats ITR-1 and ITR-2, and contains the aacC1 gentamicin resistance cassette and the ColE1 origin of replication (to permit plasmid replication in E. coli and transposon insertion site rescue) (Stewart et al., 2004). The modification in pGKT-STM1 and other STM derivatives is the addition of a unique 7-bp signature tag close to ITR2.
.
| RuvA | BB0023 | Intermediate infectivity | N (Lin et al., |
| RuvB | BB0022 | Intermediate infectivity | N (Lin et al., |
| MutS | BB0797 | Intermediate infectivity | N (Lin et al., |
| CheA1 | BB0567 | Non-infectious | T (Lin et al., |
| CheA2 | BB0669 | Non-infectious | T (Lin et al., |
| CheB1 | BB0415 | Intermediate infectivity | |
| CheB2 | BB0568 | Non-infectious | T (Lin et al., |
| CheR2 | BB0414 | Intermediate infectivity | |
| CheW2 | BB0565 | Non-infectious | |
| CheW3 | BB0670 | Non-infectious | |
| CheX | BB0671 | Non-infectious | |
| CheY2 | BB0570 | Non-infectious | |
| SulP | BB0566 | Non-infectious | |
| Mcp1 | BB0578 | Non-infectious | T (Lin et al., |
| Mcp3 | BB0597 | Non-infectious | |
| Mcp4 | BB0680 | Non-infectious | T (Lin et al., |
| Mcp5 | BB0681 | Non-infectious | T (Lin et al., |
| FliG1 | BB0221 | Non-infectious | |
| FliZ | BB0276 | Non-infectious | |
| FlbA | BB0287 | Non-infectious | T (Lin et al., |
| FliI | BB0288 | Non-infectious | T (Lin et al., |
| FliH | BB0289 | Non-infectious | T (Lin et al., |
| FlaA | BB0668 | Non-infectious | T (Lin et al., |
| FlgI | BB0772 | Non-infectious | |
| ptsG | BB0645 | Non-infectious | |
| FruA1 | BB0408 | Non-infectious | |
| FruA2 | BB0629 | Variable infectivity | |
| MalX1 | BB0116 | Intermediate infectivity | |
| MalX2 | BBB29 | Intermediate infectivity | |
| ChbB | BBB06 | Non-infectious | |
| ProX | BB0144 | Intermediate infectivity | |
| MglA | BB0318 | Non-infectious | |
| ABC transporter ATP-binding protein | BB0573 | Non-infectious | |
| OppA-2 | BB0329 | Intermediate infectivity | |
| OppA-3 | BB0330 | Intermediate infectivity | |
| OppA-4 | BBB16 | Variable infectivity | |
| OppA-5 | BBA34 | Variable infectivity | |
| BesA | BB0141 | Intermediate infectivity | |
| BesC | BB0142 | Intermediate infectivity | |
| LctP | BB0604 | Non-infectious | |
| NhaC-1 | BB0637 | Non-infectious | |
| NhaC-2 | BB0638 | Non-infectious | |
| Na+/Ca+ exchange protein | BB0164 | Intermediate infectivity | |
| GlpF | BB0240 | Intermediate infectivity | |
| GltP | BB0729 | Intermediate infectivity | |
| purine permease P1 | BBB22 | Intermediate infectivity | |
Transposon mutants lacking infectivity-related plasmids (lp25, lp28-1, lp36) or with insertions in the last 10% of the gene were excluded from this analysis. Non-infectious, mean MFI <100 and <20% of tissue sites with MFI >100. Intermediate infectivity, mean MFI between 100–500, and 20–50 percent of tissue sites with MFI >100. Variable infectivity, independent transposon mutants yielded different infectivity results. Transposon mutant STM infectivity results that have been verified by needle or tick inoculation with individual clones are shown with the pertinent reference(s).
Figure 2Mouse infectivity of transposon mutants in plasmid-encoded genes, as determined by Luminex-based STM analysis. Results obtained for genes in plasmids cp26, lp36, and lp54 are shown. For each mutant, the data represent the percent of positive tissue sites (MFI >100; blue bars) and mean MFI value (red bars) for 30–60 data points. Only clones that have all plasmids known to be required for mouse infection (cp26, lp25, lp28–1, lp36, and lp54) were analyzed. The gene designation, insertion ratio (bp from 5′ end to insertion/total bp), and description are provided. Abbreviations: HP, hypothetical protein; CHP, conserved hypothetical protein; para., paralog; pseudo., pseudogene; put. LP, putative lipoprotein; t'ase, transposase.
Advantages and disadvantages of ordered library, signature-tagged mutagenesis (STM) and Tn-seq approaches.
| STM analysis | Does not require availability of high-throughput sequencing | Requires sequence analysis of the Tn insertion points of individual clones of interest either before (ordered library) or after STM screening |
| Tn mutant clones available for further analysis after STM screening | Relatively low throughput method that requires multiple animal experiments for infectivity screening | |
| Relatively small number of clones used per experiment decreases possibility of bottleneck effects | Potential cross-contamination during clone isolation can complicate interpretation | |
| Tn-seq | Capacity to screen an entire library in a single infectivity experiment | Lack of plasmid content information; low infectivity may be related to plasmid loss |
| Does not require isolation and characterization of individual Tn mutant clones | Tn mutants of interest would have to be re-isolated for further study (if not from an ordered library) | |
| Easier application to | Possible bottleneck effects (non-uniform recovery of organisms) may necessitate use of large numbers of animals or cultures | |
| Relatively high minimum analysis cost |